OR-RADISYS
19.3.2020 09:02:04 CET | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today announced the global availability of the Radisys Engage Video Assistant (EVA), the world’s first app-less AI-powered 3-in-1 (video, voice, text) bot for digital customer interactions. The EVA empowers customer support, sales and marketing teams to significantly enhance the customer experience by delivering greater personalization that drives customer acquisition, retention, and satisfaction with the cost savings of automation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005010/en/
Customers can access the EVA to interact visually with sales professionals, subject-matter-experts, brand ambassadors, brand influencers, and customer care agents – simply by dialing a regular customer support number, using a Video over LTE (ViLTE) capable 4G/LTE or 5G smartphone, or by clicking a link on the website with no download required. The EVA can also be integrated with mobile apps. EVA’s powerful AI engine determines the customer’s intent and delivers the right information, and when required it supports the transition of the bot interaction to live agents to ensure a consistent and seamless customer experience and the most cost-effective use of live agents.
As a white label solution, the EVA offers service providers a platform with flexible deployment options, either in-network or accessible from the cloud. It enables new revenue streams by providing Video Call Bot-as-a-Service for call centers, SMBs and large enterprise customers, and it can reduce contact centers’ costs by automating interactions – like how-to interactions or sophisticated troubleshooting – that are underserved by voice or text bots alone.
Key Takeaways
- Today’s technologies provide tools that can control and improve the digital customer experience by creating self-service customer engagement. However, while chatbots, voice-enabled digital assistants, and other similar automation technologies are enabling businesses to achieve cost-effective scalability and agility, they lack a human touch needed for a satisfactory customer experience.
- The Engage Video Assistant application allows service providers, call centers and businesses to:
- Humanize existing calls and interactive mobile or voice apps with video while maintaining an authentic visual brand persona.
- Create video FAQs for new product launches or common customer support issues.
- Enhance existing bots and cumbersome interactive voice response (IVR) solutions.
- Scale influencers and brand ambassadors to unprecedented levels through personalized customer interactions.
- Engage customers at their time of choice – day or night, weekday or holiday – with personalized video interactions.
- Engage Video Assistant is deployed by Reliance Jio, the world’s largest VoLTE service provider, serving 370 million subscribers in India and helping its business customers to enhance their customer service, reduce their customer support cost, and enhance agent productivity.
“Radisys’ app-less calling experience enables businesses and service providers to offer an unprecedented in-call experience to their customers,” said Alan Quayle, independent consultant and founder, TADHack and TADHack Summit. “Its ease of integration lowers customer support costs; and improves productivity by helping customers get what they need faster, with a personal touch.”
“Video is a proven way to create greater immersion, increase click-throughs, and convert connections to purchases,” said Al Balasco, vice president, communications solutions, Radisys. “Engage Video Assistant is the first digital engagement bot application to combine video, voice and text seamlessly to provide ubiquitous and customizable brand and customer service reach for B2B and B2C customer interactions anywhere, anytime.”
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com .
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom